statistiche ricercatore

Continente	#
EU - Europa	2.248
NA - Nord America	927
AS - Asia	550
SA - Sud America	92
Continente sconosciuto - Info sul continente non disponibili	30
AF - Africa	23
Totale	3.870

Nazione	#
FI - Finlandia	1.893
US - Stati Uniti d'America	895
SG - Singapore	201
IT - Italia	144
CN - Cina	112
BR - Brasile	71
VN - Vietnam	63
PL - Polonia	47
DE - Germania	43
HK - Hong Kong	41
TW - Taiwan	40
GB - Regno Unito	27
BD - Bangladesh	23
CA - Canada	19
FR - Francia	17
JP - Giappone	15
RU - Federazione Russa	14
ID - Indonesia	13
TR - Turchia	11
IN - India	10
SE - Svezia	9
UA - Ucraina	9
AT - Austria	6
BE - Belgio	6
CO - Colombia	6
ES - Italia	6
MX - Messico	6
NL - Olanda	6
AR - Argentina	5
DK - Danimarca	5
EG - Egitto	5
ZA - Sudafrica	5
ET - Etiopia	4
IQ - Iraq	4
VE - Venezuela	4
AL - Albania	3
EC - Ecuador	3
JO - Giordania	3
KE - Kenya	3
CR - Costa Rica	2
LT - Lituania	2
MY - Malesia	2
PK - Pakistan	2
PY - Paraguay	2
RO - Romania	2
TN - Tunisia	2
UZ - Uzbekistan	2
AE - Emirati Arabi Uniti	1
AZ - Azerbaigian	1
BA - Bosnia-Erzegovina	1
BB - Barbados	1
CH - Svizzera	1
CY - Cipro	1
CZ - Repubblica Ceca	1
DZ - Algeria	1
EE - Estonia	1
GR - Grecia	1
GT - Guatemala	1
HU - Ungheria	1
IS - Islanda	1
JM - Giamaica	1
KW - Kuwait	1
KZ - Kazakistan	1
LB - Libano	1
LV - Lettonia	1
MA - Marocco	1
MU - Mauritius	1
PE - Perù	1
PH - Filippine	1
PR - Porto Rico	1
SD - Sudan	1
SK - Slovacchia (Repubblica Slovacca)	1
TH - Thailandia	1
TT - Trinidad e Tobago	1
Totale	3.840

Nome	#
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study	2.120
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial	392
High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy	314
Core needle biopsy in invasive breast cancer prognostic/predictive power: concordance with surgical speciemen and impact of immunophenotypes	228
ErbB2‐NOTCH1 axis controls autophagy in cardiac cells	184
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study	180
The Value of Semiquantitative Parameters Derived from 18F-FDG PET/CT for Predicting Response to Neoadjuvant Chemotherapy in a Cohort of Patients with Different Molecular Subtypes of Breast Cancer	176
Impact on the long-term prognosis of FDG PET/CT in luminal-A and luminal-B breast cancer	143
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)	133
Totale	3.870

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	37	0	0	0	3	1	1	7	3	2	5	3	12
2022/2023	76	8	8	3	7	8	10	5	11	10	1	5	0
2023/2024	76	1	12	4	1	7	11	2	2	1	6	16	13
2024/2025	308	6	12	23	11	30	30	10	14	57	28	45	42
2025/2026	2.830	87	41	64	85	128	70	114	79	1.946	100	73	43
2026/2027	217	46	50	106	15	0	0	0	0	0	0	0	0
Totale													3.870

SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara